🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Clear Cell RCC

The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma NCT07645690EARLY Phase 13 sites📍 Beijing📍 Beijing📍 Beijing Chinese PLA General Hospital · Tests: CLEAR CAR-T cell injection Autologous Dendritic Cell Vaccine in Kidney Cancer NCT05127824Phase 21 site📍 Pittsburgh Jodi Maranchie · Tests: Autologous alpha-DC1/TBVA vaccine, Cabozantinib KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410Phase 138 sites📍 Phoenix📍 Tucson📍 Los Angeles Kura Oncology, Inc. · Tests: Darlifarnib, Cabozantinib, Adagrasib An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer NCT06447103Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma NCT07469683Phase 21 site📍 Seoul Yonsei University · Tests: SLC-3010 + Axitinib, Axitinib Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer NCT07128680Phase 12 sites📍 Duarte📍 Irvine City of Hope Medical Center · Tests: Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formul… CAIX-targeted PET/CT in Solid Tumors NCT07833085NA1 site📍 Wuhan Zhongnan Hospital · Tests: 68Ga-CAIX Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 17 sites📍 Detroit📍 St Louis📍 Canton Sairopa B.V. · Tests: ADU-1805, Pembrolizumab Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT07011719Phase 3183 sites📍 Gilbert📍 Goodyear📍 Phoenix Arcus Biosciences, Inc. · Tests: Casdatifan, Cabozantinib, Placebo [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma NCT04989959Phase 11 site📍 Dallas Orhan Kemal Oz · Tests: [18F]PT2385, Positron Emission Tomography/Computed Tomography, Biopsy Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma NCT05214885n/a1 site📍 Jinan Qianfoshan Hospital · Tests: No intervention was required for patients or control group in this study REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma NCT07594106Phase 1, Phase 26 sites📍 Goodyear📍 Duarte📍 Tampa Regeneron Pharmaceuticals · Tests: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors NCT03972657Phase 1, Phase 224 sites📍 Gilbert📍 Phoenix📍 Tucson Regeneron Pharmaceuticals · Tests: REGN5678, Cemiplimab Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) NCT05665361Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Sasanlimab, Palbocicilib CD70-targeted immunoPET Imaging of Kidney Cancer NCT06680089Phase 21 site📍 Shanghai RenJi Hospital · Tests: [18F]RCCB6 Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer NCT07227415Phase 1, Phase 2183 sites📍 Phoenix📍 Scottsdale📍 Fayetteville Pfizer · Tests: PF-08634404, Ipilimumab, Axitinib, Casdatifan Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors NCT05263050Phase 21 site📍 Philadelphia Fox Chase Cancer Center · Tests: Cabozantinib, Nivolumab Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC NCT06863311Phase 25 sites📍 La Jolla📍 Indianapolis📍 St Louis Karie Runcie · Tests: XL092, Nivolumab Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma NCT07072234Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Lymphodepleting chemotherapy, Dexamethasone, Fludarabine, Cyclophosphamate, TGFBR-2 KO CD70 CAR NK 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study NCT06750419Phase 38 sites📍 Beijing📍 Hangzhou📍 Hubei Telix Pharmaceuticals (Innovations) Pty Limited · Tests: 89Zr-TLX250 PET/CT 68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision NCT06949215Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: 68Ga-NYM096 PET/CT Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors NCT05768464Phase 22 sites📍 Nanjing📍 Nanning The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… · Tests: Toripalimab, Axitinib Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial NCT07167329Phase 21 site📍 São Paulo José Claudio Casali da Rocha · Tests: Belzutifan Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer NCT06863857n/a2 sites📍 Bologna📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma NCT07688187Phase 11 site📍 Omaha PeptiDream Inc. · Tests: PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide) A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NCT06805825Phase 15 sites📍 Ann Arbor📍 Cleveland📍 Portland Novelty Nobility, Inc. · Tests: NN3201
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy